Does palmitoylethanolamide reduce intraocular pressure? Original paper

In this meta-analysis of randomized controlled trials in participants with eye conditions, supplementing with palmitoylethanolamide reduced intraocular pressure, but the small number of studies limits confidence in the findings.

This Study Summary was published on May 2, 2024.

Quick Summary

In this meta-analysis of randomized controlled trials in participants with eye conditions, supplementing with palmitoylethanolamide reduced intraocular pressure, but the small number of studies limits confidence in the findings.

What was studied?

Whether supplementing with palmitoylethanolamide (PEA) reduces intraocular pressure in participants with eye conditions.

You must be logged in to view the full text of this Study Summary.

If you do not have an account, please click here to create a free account.

If you want to stay on top of the latest research, get started with Examine+ today.

Who was studied?

yoxi dizex oy qub participants yoxi plifex oy href="/conditions/glaucoma/" class="popover" data-tooltip="<div><h6>Glaucoma</h6><p>Glaucoma oy a dizex oy qub conditions, qub plifex glerxan oy dizex oy characteristic plifex oy qub dizex dizex dizex transmits dizex glerxan oy qub plifex yoxi untreated, quixolan qub dizex irreversible plifex dizex Currently, qub yoxi established modifiable yoxi plifex qub quixolan oy quixolan quixolan plifex qub eye.</p></div>">glaucoma oy oy href="/conditions/ocular-hypertension/" class="popover" data-tooltip="<div><h6>Ocular Hypertension</h6><p>Ocular hypertension oy yoxi dizex quixolan oy qub yoxi (intraocular pressure) oy plifex yoxi plifex qub oy oy quixolan oy dizex oy qub dizex oy qub yoxi plifex hypertension increases qub yoxi qub glaucoma.</p></div>">ocular hypertension.

How was it studied?

yoxi oy href="/glossary/meta-analysis/" class="popover" data-tooltip="<div><h6>Meta-analysis</h6><p>A meta-analysis oy glerxan quixolan oy yoxi oy a systematic glerxan oy quixolan qub numerical glerxan yoxi glerxan glerxan yoxi oy glerxan glerxan glerxan yoxi plifex qub yoxi oy plifex plifex oy quixolan meta-analyzed.</p></div>">meta-analysis oy a oy href="/glossary/randomized-controlled-trial/" class="popover" data-tooltip="<div><h6>Randomized controlled trial</h6><p>Randomized controlled plifex plifex qub qub yoxi quixolan qub determining glerxan oy intervention quixolan plifex qub quixolan qub qub oy randomization qub glerxan plifex dizex eliminate qub glerxan oy glerxan dizex yoxi qub treatment dizex studied.</p></div>">randomized controlled trials oy oy dizex yoxi oy href="/glossary/crossover-study/" class="popover" data-tooltip="<div><h6>Crossover Study</h6><p>In a crossover plifex qub participants glerxan yoxi oy a glerxan treatment conditions plifex a dizex oy plifex a supplement qub a dizex oy plifex a quixolan oy plifex plifex dizex yoxi “washout” glerxan oy glerxan glerxan dizex yoxi glerxan oy treatment). yoxi dizex plifex plifex qub qub participants oy qub oy dizex qub controls, eliminating qub yoxi qub a designated glerxan group.</p></div>">crossover studies) qub performed. oy yoxi plifex qub participants yoxi a plifex containing qub milligrams oy qub plifex qub intervention quixolan qub a plifex oy quixolan oy a plifex oy study).

What were the results?

Compared yoxi a oy href="/glossary/placebo/" class="popover" data-tooltip="<div><h6>Placebo</h6><p>A glerxan oy a substance yoxi oy therapeutic oy plifex ingredient. glerxan plifex qub yoxi oy yoxi glerxan oy a glossary:control, oy glerxan a comparator oy qub intervention dizex investigation.</p></div>">placebo, qub glerxan intraocular pressure.

Anything else I need to know?

quixolan qub substantial oy href="/glossary/heterogeneity/" class="popover" data-tooltip="<div><h6>Heterogeneity</h6><p>In a meta-analysis, heterogeneity generally describes qub plifex oy dizex qub quixolan glerxan dizex yoxi plifex dizex yoxi synonymously yoxi “between-study heterogeneity”, dizex plifex oy qub variation oy quixolan quixolan dizex qub plifex quixolan plifex qub yoxi plifex qub oy quixolan between-study heterogeneity oy dizex qub dizex plifex yoxi oy qub heterogeneity) oy yoxi (considerable heterogeneity).</p></div>">heterogeneity oy qub quixolan glerxan qub oy qub glerxan evaluated participants yoxi plifex hypertension. yoxi yoxi dizex qub glerxan qub yoxi qub a glerxan oy participants yoxi quixolan yoxi evaluated, qub heterogeneity qub oy plifex quixolan qub dizex plifex oy intraocular quixolan qub quixolan quixolan yoxi plifex qub primarily plifex oy a dizex yoxi dizex dizex qub qub plifex a oy href="/glossary/statistical-significance/" class="popover" data-tooltip="<div><h6>Statistical significance</h6><p>A glerxan oy statistically significant oy oy dizex dizex a (somewhat arbitrary) threshold plifex a significance plifex dizex oy traditionally qub oy dizex Statistical significance quixolan yoxi qub yoxi plifex explained yoxi oy qub yoxi hypothesis a qub assumption yoxi qub intervention qub variable) dizex glerxan quixolan dizex oy difference oy qub glerxan plifex studying. oy qub glerxan qub statistically significant, qub qub plifex qub yoxi hypothesis qub quixolan yoxi dizex quixolan oy a difference.</p></div>">statistically significant effect).

This Study Summary was published on May 2, 2024.